Oral water soluble contrast for malignant bowel obstruction
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Oral Water Soluble Contrast for Malignant Bowel Obstruction." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431382/all/Cabergoline_versus_bromocriptine_for_levodopa‐induced_complications_in_Parkinson's_disease_Edited__no_change_to_conclusions_. Accessed 18 April 2024.
Oral water soluble contrast for malignant bowel obstruction. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431382/all/Cabergoline_versus_bromocriptine_for_levodopa‐induced_complications_in_Parkinson's_disease_Edited__no_change_to_conclusions_. Accessed April 18, 2024.
Oral water soluble contrast for malignant bowel obstruction. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/431382/all/Cabergoline_versus_bromocriptine_for_levodopa‐induced_complications_in_Parkinson's_disease_Edited__no_change_to_conclusions_
Oral Water Soluble Contrast for Malignant Bowel Obstruction [Internet]. In: Cochrane Abstracts. [cited 2024 April 18]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431382/all/Cabergoline_versus_bromocriptine_for_levodopa‐induced_complications_in_Parkinson's_disease_Edited__no_change_to_conclusions_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Oral water soluble contrast for malignant bowel obstruction
ID - 431382
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431382/all/Cabergoline_versus_bromocriptine_for_levodopa‐induced_complications_in_Parkinson's_disease_Edited__no_change_to_conclusions_
DB - Evidence Central
DP - Unbound Medicine
ER -